Adverum Biotechnologies (NASDAQ: ADVM) is one of 298 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Adverum Biotechnologies to similar businesses based on the strength of its analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.


This table compares Adverum Biotechnologies and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Adverum Biotechnologies -3,552.21% -25.09% -23.01%
Adverum Biotechnologies Competitors -5,409.43% -437.09% -41.74%

Institutional and Insider Ownership

30.1% of Adverum Biotechnologies shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 7.8% of Adverum Biotechnologies shares are held by company insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Adverum Biotechnologies and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Adverum Biotechnologies $1.46 million -$113.74 million -2.18
Adverum Biotechnologies Competitors $290.00 million $35.57 million -5.02

Adverum Biotechnologies’ competitors have higher revenue and earnings than Adverum Biotechnologies. Adverum Biotechnologies is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and target prices for Adverum Biotechnologies and its competitors, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adverum Biotechnologies 0 1 1 0 2.50
Adverum Biotechnologies Competitors 769 3078 11287 227 2.71

Adverum Biotechnologies presently has a consensus price target of $4.75, suggesting a potential upside of 41.79%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 24.71%. Given Adverum Biotechnologies’ higher possible upside, equities analysts clearly believe Adverum Biotechnologies is more favorable than its competitors.

Risk and Volatility

Adverum Biotechnologies has a beta of 2.49, meaning that its share price is 149% more volatile than the S&P 500. Comparatively, Adverum Biotechnologies’ competitors have a beta of 6.53, meaning that their average share price is 553% more volatile than the S&P 500.


Adverum Biotechnologies competitors beat Adverum Biotechnologies on 8 of the 12 factors compared.

Adverum Biotechnologies Company Profile

Adverum Biotechnologies, Inc., formerly Avalanche Biotechnologies, Inc., is a gene therapy company. The Company is engaged in discovering and developing medicines to patients suffering from chronic or debilitating disease. The Company operates and manages its business in the segment of developing and commercializing gene therapeutics. It focuses on diseases with unmet medical need, including ophthalmic diseases, such as wet age-related macular degeneration (AMD), as well as rare genetic diseases. The Company’s product candidates include AVA-101 and AVA-201 for treatment of Wet AMD; AVA-322 and AVA-323 for the treatment of Color Vision Deficiency, and AVA-311 for the treatment of Juvenile X-linked Retinoschisis. It has generated human proof-of-concept data for AVA-101 in a Phase I trial with over eight wet AMD subjects conducted at Lions Eye Institute (LEI) in Australia. It is developing AVA-322 and AVA-323 for the treatment of color vision deficiency (CVD).

Receive News & Stock Ratings for Adverum Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies Inc. and related stocks with our FREE daily email newsletter.